Skip to content
OpenCapital
Get started

Replimune Group REPL Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Immunovant, Inc. logo
Immunovant, Inc.IMVT
——

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Replimune Group (REPL) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $14.1 in Q4 2025.
How has Replimune Group's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Replimune Group's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price decreased by 7.7% year-over-year, from $15.28 to $14.1.
What is the long-term trend for Replimune Group's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 4 years (2021 to 2025), Replimune Group's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a 3.5% compound annual growth rate (CAGR), from $13.26 to $15.22.